GlassScriptPhysician profile
Amber Duncan
NPI 1770964819
$43,599.99
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16K · 2022: $13K · 2023: $10K · 2024: $4,397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $1,382 · Travel and Lodging: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,925.00 |
| Food and Beverage | $1,381.53 |
| Travel and Lodging | $283.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $41,259.15 | 2021-2024 | |
| Allergan, INC. | $750.00 | 2021 | |
| Lilly USA, LLC | $449.52 | 2021-2023 | Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.24 | 2021-2023 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $160.82 | 2023-2024 | Xifaxan |
| Novo Nordisk INC | $135.13 | 2021-2023 | Rybelsus, Ozempic |
| Biohaven Pharmaceuticals, INC. | $128.06 | 2021 | |
| Merck Sharp & Dohme LLC | $114.20 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Pfizer INC. | $84.10 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $54.89 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $54.50 | 2021 | |
| Amgen INC. | $38.29 | 2023-2024 | Repatha, Otezla |
| Cardiovascular Systems INC. | $23.50 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $21.85 | 2021 | |
| Sumitomo Pharma America, INC. | $19.69 | 2023 | Gemtesa |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medline Industries LP | $19.31 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $19.19 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.00 | 2021 | |
| Impel Pharmaceuticals INC. | $14.55 | 2023 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Duncan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.